New asthma drug shows promise in early trial
NCT ID NCT06748053
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new medicine called GSK5784283 for adults with asthma that is not well controlled by their current treatments. The medicine blocks a protein called TSLP that can cause inflammation in the lungs. The trial will involve about 300 people and aims to find the best dose to improve lung function and asthma control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK5784283 (anti-TSLP antibody)
What this could lead to
If successful, this could lead to a new long-lasting treatment option for people whose asthma is not well controlled with current therapies.
What could go wrong
This is an early Phase 2 dose-finding study, so it is not yet proven to work. The results may not lead to a new treatment, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Little Rock, Arkansas, 72205, United States
-
GSK Investigational Site
Long Beach, California, 90815, United States
-
GSK Investigational Site
Los Angeles, California, 90025, United States
-
GSK Investigational Site
Redding, California, 96001, United States
-
GSK Investigational Site
Riverside, California, 92506, United States
-
GSK Investigational Site
Sacramento, California, 95817, United States
-
GSK Investigational Site
San Jose, California, 95117, United States
-
GSK Investigational Site
Colorado Springs, Colorado, 80923, United States
-
GSK Investigational Site
Lakewood, Colorado, 80228-1813, United States
-
GSK Investigational Site
Wheat Ridge, Colorado, 80033, United States
-
GSK Investigational Site
New Haven, Connecticut, 06511, United States
-
GSK Investigational Site
Aventura, Florida, 33180, United States
-
GSK Investigational Site
Hialeah, Florida, 33012, United States
-
GSK Investigational Site
Lake Worth, Florida, 33460, United States
-
GSK Investigational Site
Leesburg, Florida, 34748, United States
-
GSK Investigational Site
Miami, Florida, 33144, United States
-
GSK Investigational Site
Miami, Florida, 33166, United States
-
GSK Investigational Site
Miami, Florida, 33172, United States
-
GSK Investigational Site
Miami, Florida, 33173, United States
-
GSK Investigational Site
Plantation, Florida, 33324, United States
-
GSK Investigational Site
Tampa, Florida, 33607, United States
-
GSK Investigational Site
Skokie, Illinois, 60077, United States
-
GSK Investigational Site
Shreveport, Louisiana, 71105, United States
-
GSK Investigational Site
Lathrup Village, Michigan, 48076, United States
-
GSK Investigational Site
Warren, Michigan, 48088, United States
-
GSK Investigational Site
Omaha, Nebraska, 68198, United States
-
GSK Investigational Site
The Bronx, New York, 10461, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45236, United States
-
GSK Investigational Site
DuBois, Pennsylvania, 15801, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19140, United States
-
GSK Investigational Site
Pittsburgh, Pennsylvania, 15241, United States
-
GSK Investigational Site
Wyomissing, Pennsylvania, 19610, United States
-
GSK Investigational Site
Warwick, Rhode Island, 02886, United States
-
GSK Investigational Site
Greenville, South Carolina, 29607, United States
-
GSK Investigational Site
Spartanburg, South Carolina, 29303, United States
-
GSK Investigational Site
Knoxville, Tennessee, 37909, United States
-
GSK Investigational Site
Boerne, Texas, 78006, United States
-
GSK Investigational Site
Cypress, Texas, 77429, United States
-
GSK Investigational Site
Dallas, Texas, 75225, United States
-
GSK Investigational Site
Houston, Texas, 77058, United States
-
GSK Investigational Site
Kerrville, Texas, 78028, United States
-
GSK Investigational Site
McKinney, Texas, 75069, United States
-
GSK Investigational Site
San Antonio, Texas, 78212, United States
-
GSK Investigational Site
San Antonio, Texas, 78229, United States
-
GSK Investigational Site
Sherman, Texas, 75092, United States
-
GSK Investigational Site
American Fork, Utah, 84003, United States
-
GSK Investigational Site
Pleasant View, Utah, 84404, United States
-
GSK Investigational Site
Salt Lake City, Utah, 84117, United States
-
GSK Investigational Site
South Ogden, Utah, 84405, United States
-
GSK Investigational Site
Bellingham, Washington, 98225, United States
-
GSK Investigational Site
Blagoevgrad, 2700, Bulgaria
-
GSK Investigational Site
Gorna Oryahovitsa, 5100, Bulgaria
-
GSK Investigational Site
Lovech, 5500, Bulgaria
-
GSK Investigational Site
Pazardzhik, 4400, Bulgaria
-
GSK Investigational Site
Plovdiv, 4002, Bulgaria
-
GSK Investigational Site
Rousse, 7000, Bulgaria
-
GSK Investigational Site
Rousse, 7002, Bulgaria
-
GSK Investigational Site
Sofia, 1000, Bulgaria
-
GSK Investigational Site
Sofia, 1142, Bulgaria
-
GSK Investigational Site
Sofia, 1233, Bulgaria
-
GSK Investigational Site
Sofia, 1431, Bulgaria
-
GSK Investigational Site
Sofia, 1680, Bulgaria
-
GSK Investigational Site
Stara Zagora, Bulgaria
-
GSK Investigational Site
Varna, 9000, Bulgaria
-
GSK Investigational Site
Vratsa, 3000, Bulgaria
-
GSK Investigational Site
Kelowna, British Columbia, V1Y 4N7, Canada
-
GSK Investigational Site
Ajax, Ontario, L1S 2J5, Canada
-
GSK Investigational Site
London, Ontario, N6A 4V2, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 1E2, Canada
-
GSK Investigational Site
Windsor, Ontario, N8X 1T3, Canada
-
GSK Investigational Site
Trois-Rivières, Quebec, G8T 7A1, Canada
-
GSK Investigational Site
Brandýs nad Labem, 25001, Czechia
-
GSK Investigational Site
Mladá Boleslav, 293 01, Czechia
-
GSK Investigational Site
Teplice, 415 01, Czechia
-
GSK Investigational Site
Bendorf, 56170, Germany
-
GSK Investigational Site
Berlin, 10961, Germany
-
GSK Investigational Site
Berlin, 12203, Germany
-
GSK Investigational Site
Darmstadt, 64283, Germany
-
GSK Investigational Site
Frankfurt, 60596, Germany
-
GSK Investigational Site
Fürstenwalde, 15517, Germany
-
GSK Investigational Site
Leipzig, 04347, Germany
-
GSK Investigational Site
Magdeburg, 39120, Germany
-
GSK Investigational Site
Mainz, 55128, Germany
-
GSK Investigational Site
München, 81241, Germany
-
GSK Investigational Site
Neu-Isenburg, 63263, Germany
-
GSK Investigational Site
Schleswig, 24837, Germany
-
GSK Investigational Site
Chiba, 275-8580, Japan
-
GSK Investigational Site
Fukui, 910-8526, Japan
-
GSK Investigational Site
Fukuoka, 806-8501, Japan
-
GSK Investigational Site
Fukuoka, 811-1394, Japan
-
GSK Investigational Site
Fukushima, 960-1295, Japan
-
GSK Investigational Site
Gifu, 509-6134, Japan
-
GSK Investigational Site
Hiroshima, 734-8530, Japan
-
GSK Investigational Site
Hokkaido, 064-0804, Japan
-
GSK Investigational Site
Hyōgo, 653-0013, Japan
-
GSK Investigational Site
Kagawa, 762-0043, Japan
-
GSK Investigational Site
Kanagawa, 236-0051, Japan
-
GSK Investigational Site
Mie, 515-8544, Japan
-
GSK Investigational Site
Nagasaki, 852-8501, Japan
-
GSK Investigational Site
Okayama, 702-8055, Japan
-
GSK Investigational Site
Osaka, 596-8501, Japan
-
GSK Investigational Site
Shizuoka, 420-8527, Japan
-
GSK Investigational Site
Tokyo, 141-8625, Japan
-
GSK Investigational Site
Tokyo, 162-8655, Japan
-
GSK Investigational Site
Tokyo, 204-8585, Japan
-
GSK Investigational Site
Yokohama, 232-0024, Japan
-
GSK Investigational Site
Bacau, 600252, Romania
-
GSK Investigational Site
Brasov, 500283, Romania
-
GSK Investigational Site
Brasov, 500366, Romania
-
GSK Investigational Site
Bucharest, 050159, Romania
-
GSK Investigational Site
Cluj-Napoca, 400139, Romania
-
GSK Investigational Site
Craiova Dolj, 200515, Romania
-
GSK Investigational Site
Timișoara, 300310, Romania
-
GSK Investigational Site
Alcorcon Madrid, 28922, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Barcelona, Spain
-
GSK Investigational Site
Benalmádena, 29631, Spain
-
GSK Investigational Site
Jerez de la Frontera, 11407, Spain
-
GSK Investigational Site
Madrid, 28003, Spain
-
GSK Investigational Site
Madrid, 28007, Spain
-
GSK Investigational Site
Madrid, 28031, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28223, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
-
GSK Investigational Site
Santander, 39008, Spain
-
GSK Investigational Site
Seville, 41012, Spain
-
GSK Investigational Site
Valencia, 46015, Spain
-
GSK Investigational Site
Valencia, 46017, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Bradford, BD9 6RJ, United Kingdom
-
GSK Investigational Site
London, EC1M 6BQ, United Kingdom
-
GSK Investigational Site
London, SE1 9RT, United Kingdom
-
GSK Investigational Site
Newcastle upon Tyne, NE1 4LP, United Kingdom